{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:04:08Z","timestamp":1776557048302,"version":"3.51.2"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Trastuzumab is part of the standard treatment in patients with human epidermal growth factor receptor 2-positive early breast cancer in addition to (neo)adjuvant chemotherapy. This German prospective noninterventional study, which included major patient cohorts underrepresented in the pivotal randomized studies, examined the generalizability of the results of those studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Between 2006 and 2012, 4,027 patients were enrolled and treated with trastuzumab; they were unselected regarding age or concomitant\/sequential adjuvant chemotherapy. Long-term outcome data were obtained in yearly intervals. All analyses were descriptive in nature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 3,940 evaluable patients, 26% were elderly (older than 65 years of age). More than half of the population had pN0 tumor stage. Ninety-four percent received chemotherapy: 78% as adjuvant treatment and 14% as neoadjuvant treatment, 2% both. Anthracyclines were administered in 87% and taxanes in 66%. Trastuzumab was stopped prematurely in 9% (because of cardiotoxicity in 3.5%). Recurrence-free survival was 90.0% (95% confidence interval [CI], 88.9%\u201391.1%) and 82.8% (95% CI, 81.2%\u201384.4%) after 3 and 5 years, respectively. The corresponding figures for overall survival were 96.8% (95% CI, 96.1%\u201397.6%) and 90.0% (95% CI, 88.6%\u201391.4%). Pathological primary tumor size, lymph node involvement, and hormone receptor status had the greatest independent effect on recurrence risk. Cardiac function toxicity of National Cancer Institute common toxicity criteria grade \u22652 and \u22653 was observed in 2.5% and less than 1% of patients, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The maturing follow-up data seem to confirm the beneficial results of trastuzumab treatment for early breast cancer from the randomized studies. Moreover, these findings support use of trastuzumab-based therapy in patients groups less commonly included in the phase III trials (e.g., elderly patients and those with stage I disease).<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2016-0193","type":"journal-article","created":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T02:20:18Z","timestamp":1486520418000},"page":"131-138","source":"Crossref","is-referenced-by-count":11,"title":["Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany"],"prefix":"10.1093","volume":"22","author":[{"given":"Peter","family":"Dall","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology and Breast Cancer Center Klinikum L\u00fcneburg, L\u00fcneburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Koch","sequence":"additional","affiliation":[{"name":"Breast Center, Klinikum N\u00fcrnberg, N\u00fcrnberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"G\u00f6hler","sequence":"additional","affiliation":[{"name":"Onkozentrum Dresden\/Freiberg, Dresden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Selbach","sequence":"additional","affiliation":[{"name":"Oncology Practice, Duisburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Ammon","sequence":"additional","affiliation":[{"name":"Oncology Practice, G\u00f6ttingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Eggert","sequence":"additional","affiliation":[{"name":"Oncology Practice, Moers, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidal","family":"Gazawi","sequence":"additional","affiliation":[{"name":"Gyneco-Oncology Practice, Leipzig, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Rezek","sequence":"additional","affiliation":[{"name":"Gynecology, Marien-Hospital, Wesel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Wischnik","sequence":"additional","affiliation":[{"name":"Department of Gynecology Klinikum Augsburg, Augsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Hielscher","sequence":"additional","affiliation":[{"name":"Gyneco-Oncology Practice, Stralsund, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Keitel","sequence":"additional","affiliation":[{"name":"Roche Pharma AG, Grenzach-Wyhlen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Cirrincione","sequence":"additional","affiliation":[{"name":"WiSP Research Institute, Langenfeld, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Hinke","sequence":"additional","affiliation":[{"name":"WiSP Research Institute, Langenfeld, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Feisel-Schwickardi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology and Breast Cancer Center, Klinikum Kassel, Kassel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,9,18]]},"reference":[{"key":"2021122506432406100_onco12015-bib-0001","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.breast.2013.11.011","article-title":"Treatment of HER2-positive breast cancer","volume":"23","author":"Figueroa-Magalhaes","year":"2014","journal-title":"Breast"},{"key":"2021122506432406100_onco12015-bib-0002","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring therapies\u2014improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015","volume":"26","author":"Coates","year":"2015","journal-title":"Ann Oncol"},{"key":"2021122506432406100_onco12015-bib-0003","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1200\/JCO.2012.42.0695","article-title":"Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?","volume":"30","author":"Burstein","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122506432406100_onco12015-bib-0004","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2 year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"2021122506432406100_onco12015-bib-0005","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","article-title":"Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31","volume":"29","author":"Perez","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122506432406100_onco12015-bib-0006","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122506432406100_onco12015-bib-0007","first-page":"CD006243","article-title":"Trastuzumab containing regimens for early breast cancer","author":"Moja","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"key":"2021122506432406100_onco12015-bib-0008","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","article-title":"Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review","volume":"28","author":"Dawood","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122506432406100_onco12015-bib-0009","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ctrv.2013.04.002","article-title":"Trastuzumab in small tumours and in elderly women","volume":"40","author":"Albanell","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"2021122506432406100_onco12015-bib-0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ctrv.2012.03.009","article-title":"Adjuvant trastuzumab in elderly with HER2-positive breast cancer: A systematic review of randomized controlled trials","volume":"39","author":"Brollo","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"2021122506432406100_onco12015-bib-0011","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2174\/18715206113139990087","article-title":"Targeted anti-HER2 cancer therapy in elderly women diagnosed with breast cancer","volume":"14","author":"Molina-Garrido","year":"2014","journal-title":"Anticancer Agents Med Chem"},{"key":"2021122506432406100_onco12015-bib-0012","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/cncr.29060","article-title":"Systemic therapy for early-stage HER2-positive breast cancers: Time for a less-is-more approach?","volume":"121","author":"Paplomata","year":"2015","journal-title":"Cancer"},{"key":"2021122506432406100_onco12015-bib-0013","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/cncr.27831","article-title":"Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race\/ethnicity and education within the National Comprehensive Cancer Network","volume":"119","author":"Freedman","year":"2013","journal-title":"Cancer"},{"key":"2021122506432406100_onco12015-bib-0014","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/1471-2407-14-307","article-title":"The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2\u2013positive metastatic breast cancer","volume":"14","author":"Tripathy","year":"2014","journal-title":"BMC Cancer"},{"key":"2021122506432406100_onco12015-bib-0015","first-page":"34","article-title":"Directive 2001\/20\/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use","volume":"L121","author":"European Commission","year":"2001","journal-title":"OJ."},{"issue":"Part 2","key":"2021122506432406100_onco12015-bib-0016","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2307\/2344317","article-title":"Asymptotically efficient rank invariant test procedures","volume":"135","author":"Peto","year":"1972","journal-title":"J R Stat Soc A"},{"key":"2021122506432406100_onco12015-bib-0017","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J Roy Stat Soc B"},{"key":"2021122506432406100_onco12015-bib-0018","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000324048","article-title":"Adopting guidelines into clinical practice: Implementation of trastuzumab in the adjuvant treatment of breast cancer in Lower Saxony, Germany, in 2007","volume":"6","author":"Liebrich","year":"2011","journal-title":"Breast Care (Basel)"},{"key":"2021122506432406100_onco12015-bib-0019","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2012.44.1956","article-title":"Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: Results from a herceptin adjuvant trial","volume":"31","author":"Partridge","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122506432406100_onco12015-bib-0020","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jgo.2015.06.003","article-title":"Trastuzumab in the treatment of elderly patients with early breast cancer\u2014results from an observational study in Germany","volume":"6","author":"Dall","year":"2015","journal-title":"J Geriatr Oncol"},{"key":"2021122506432406100_onco12015-bib-0021","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1470-2045(10)70119-4","article-title":"Management of small HER2-positive breast cancers","volume":"11","author":"Banerjee","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122506432406100_onco12015-bib-0022","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/annonc\/mdq786","article-title":"Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?","volume":"22","author":"Kelly","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122506432406100_onco12015-bib-0023","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1634\/theoncologist.2015-0006","article-title":"Real-life use and effectiveness of adjuvant trastuzumab in early breast cancer patients: A study of the Southeast Netherlands Breast Cancer Consortium","volume":"20","author":"Seferina","year":"2015","journal-title":"The Oncologist"},{"key":"2021122506432406100_onco12015-bib-0024","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/bjc.2011.506","article-title":"Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales?","volume":"106","author":"Webster","year":"2012","journal-title":"Br J Cancer"},{"key":"2021122506432406100_onco12015-bib-0025","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1200\/JCO.2014.58.9465","article-title":"Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older patients with breast cancer","volume":"33","author":"Chavez-MacGregor","year":"2015","journal-title":"J Clin Oncol."},{"key":"2021122506432406100_onco12015-bib-0026","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","article-title":"Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial","volume":"28","author":"Procter","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122506432406100_onco12015-bib-0027","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","article-title":"Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"60","author":"Chen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2021122506432406100_onco12015-bib-0028","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/annonc\/mdn005","article-title":"Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial","volume":"19","author":"Untch","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122506432406100_onco12015-bib-0029","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122506432406100_onco12015-bib-0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/annonc\/mdq304","article-title":"Small HER2-positive, node-negative breast cancer: Who should receive systemic adjuvant treatment?","volume":"22","author":"Joerger","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122506432406100_onco12015-bib-0031","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1200\/JCO.2015.60.8620","article-title":"Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2\u2013positive early breast cancer and tumors\u2009\u2264\u20092 cm: a meta-analysis of the randomized trastuzumab trials","volume":"33","author":"O\u2019Sullivan","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122506432406100_onco12015-bib-0032","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12916-014-0132-3","article-title":"Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: Focus on new data from clinical trials","volume":"12","author":"Lavaud","year":"2014","journal-title":"BMC Med"},{"key":"2021122506432406100_onco12015-bib-0033","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1055\/s-0035-1546120","article-title":"Primary therapy of patients with early breast cancer: Evidence, controversies, consensus","volume":"75","author":"Untch","year":"2015","journal-title":"Geburtshilfe Frauenheilkd"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0193","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0193","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/2\/131\/41913692\/oncolo_22_2_131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/2\/131\/41913692\/oncolo_22_2_131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T10:28:11Z","timestamp":1719052091000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/2\/131\/6437697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,1]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,9,18]]},"published-print":{"date-parts":[[2017,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0193","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,2,1]]},"published":{"date-parts":[[2017,2,1]]}}}